Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extending the Authorised Indications for Obinutuzumab

New indication concerns a combination with bendamustine in patients with follicular lymphoma who were previously treated with chemotherapy
04 May 2016
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 28 April 2016, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product obinutuzumab (Gazyvaro).

The marketing authorisation holder for this medicinal product is Roche Registration Limited.

The CHMP adopted a new indication as follows:

Follicular Lymphoma (FL)

Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

Gazyvaro was first authorised in the European Union (EU) in July 2014 for use in combination with chlorambucil in patients with previously untreated chronic lymphocytic leukaemia (CLL).

While effective treatments exist for FL, the disease often comes back and becomes increasingly aggressive and resistant to existing treatment options. Patients whose disease has become aggressive often die after one to two years.

The active substance in Gazyvaro is a monoclonal antibody that targets B-lymphocytes and triggers the death of cancer cells through the activation of the immune system.

The recommendation from EMA’s CHMP is based on the results of a phase III trial that compared the effects of Gazyvaro given in combination with bendamustine and followed by Gazyvaro as a maintenance treatment, with the effects of bendamustine alone, in 321 patients with FL who did not respond to or whose disease progressed with chemotherapy. In this study, patients treated with Gazyvaro in combination with bendamustine lived longer without their disease progressing compared to patients treated with bendamustine alone (on average about 29 months compared to 14 months).

The most common side effects reported with the combination of Gazyvaro and bendamustine were consistent with the known safety profiles of the individual medicines.

Because FL is rare, Gazyvaro was designated as an orphan medicine in 2015. Orphan designation is the key instrument available in the EU to encourage the development of medicines for patients with rare diseases. Orphan-designated medicines qualify for ten years’ market exclusivity. In addition, the designation gives medicine developers access to incentives, such as fee reductions for marketing authorisation applications and for scientific advice.

The applicant received scientific advice from the CHMP on the design of the phase III trial supporting the application.

The opinion adopted by the CHMP at its April 2016 meeting is an intermediary step on Gazyvaro’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on EU-wide marketing authorisations. Once the extension of indication has been granted, a decision about price and reimbursement will take place at the level of each Member State considering the potential role/use of this medicine in the context of the national health system of that country.

Last update: 04 May 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.